Cursor reached $40 million ARR per employee while Medvi generated $401 million in revenue with two employees — then received FDA warning letters. The capital efficiency gains are real and measurable, but they're arriving alongside regulatory complexity that lean models weren't built to handle.
This paradox defines the current moment: AI-native companies achieve unprecedented capital efficiency precisely as operational complexity increases. Companies like Medvi compress traditional business functions into small teams, then discover that regulatory compliance doesn't scale with headcount efficiency.
The data reveals a structural shift where capital efficiency and operational complexity grow in parallel. Sapphire's 2026 report counts 80+ AI-native companies at $100M+ ARR, achieving 5-10x better revenue-per-employee than public B2B software companies, while compressing time-to-$100M from five years to under 18 months.
The Medvi case illustrates the challenge: extreme lean operations generating massive revenue while struggling with regulatory frameworks designed for traditional organizational structures. This tension between capital efficiency and compliance complexity will define which AI-native companies scale sustainably versus which achieve rapid growth followed by operational constraints.